# Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

> **NCT02917096** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Fludarabine
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **OTHER:** Pharmacological Study
- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib Phosphate
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02917096
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-13
- **Primary completion:** 2020-04-16
- **Final completion:** 2023-08-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02917096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02917096, "Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02917096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*